Aventis Pharmaceuticals Inc.

Aventis Pharma Limited

Stephanie Daniele Deprets

Michael Edwards

Brian Leslie Pedgrift

Frank Halley

Tahir Nadeem Majid

Shelley Amendola

Iain Mclay

Paul J. Cox

David Aldous

Christopher Edlin

Bernard Baudoin

Christopher D Edlin

Paul Joseph Cox

Michael L Edwards

Andrew David Morley

Stephanie Deprets

Brian L Pedgrift

Herve Bouchard

Charles J Gardner

Timothy A Gillespy

Didier Babin

Dominique Damour

John Charles Reader

Conception Nemecek

Francois Clerc

Michael Cherry

Dorothea Kominos

Chantal Carrez

Justine Yeun Quai Lai

Laurence Gauzy

Nawaz Mohammed Khan

Olivier Houille

Lloyd J Payne

Daniel N A Bezard

Alain Le-Brun

David John Aldous

Iain M McLay

Stephanie D Deprets

Justine Y Q Lai

Paul J Cox

The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Benzimidazoles

The invention is directed to physiologically active compounds of general formula (I):&#x2014; and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles for inhibiting aurora2 and other kinases

Compounds of the formula and N-oxides, prodrugs, acid bioisosteres, pharmaceutically acceptable salts or solvates of such compounds, or N-oxides, prodrugs, or acid bioisosteres of such salts or solvates, to compositions comprising such compounds, and methods of treatment comprising administering, to a patient in need thereof, such compounds and compositions.

Pyrrolopyrimidines

The invention is directed to physiologically active compounds of general formula (I):and compositions containing such compounds; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (I). Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Azaindoles

The invention is directed to physiologically active compounds of the general formula (Ix)and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

Growing community of inventors

Newark, United Kingdom

Christopher D Edlin